Janux Therapeutics Inc Forecast, price target & analysts
Janux Therapeutics Inc Target price 2025 - Analyst rating & recommendation
Janux Therapeutics Inc Classifications & Recommendation:
Janux Therapeutics Inc Price Target
| Target Price | $75.48 |
| Price | $28.52 |
| Potential |
164.66%
register free of charge
|
| Number of Estimates | 18 |
|
18 Analysts have issued a price target Janux Therapeutics Inc 2026 .
The average Janux Therapeutics Inc target price is $75.48.
This is
164.66%
register free of charge
$210.00
636.33%
register free of charge
$25.25
11.47%
register free of charge
|
|
| A rating was issued by 24 analysts: 23 Analysts recommend Janux Therapeutics Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Janux Therapeutics Inc stock has an average upside potential 2026 of
164.66%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 10.59 | 2.92 |
| 31.06% | 72.39% | |
| EBITDA Margin | -913.98% | -6,018.95% |
| 3.98% | 558.55% | |
| Net Margin | -651.46% | -4,797.68% |
| 9.70% | 636.45% |
18 Analysts have issued a sales forecast Janux Therapeutics Inc 2025 . The average Janux Therapeutics Inc sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Janux Therapeutics Inc EBITDA forecast 2025. The average Janux Therapeutics Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
19 Janux Therapeutics Inc Analysts have issued a net profit forecast 2025. The average Janux Therapeutics Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.28 | -2.33 |
| 3.03% | 82.03% | |
| P/E | negative | |
| EV/Sales | 255.64 |
19 Analysts have issued a Janux Therapeutics Inc forecast for earnings per share. The average Janux Therapeutics Inc EPS is
This results in the following potential growth metrics and future valuations:
Janux Therapeutics Inc...
Current Janux Therapeutics Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Locked
➜
Locked
|
Locked | Nov 07 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Sep 17 2025 |
| Stifel |
Locked
➜
Locked
|
Locked | Sep 10 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Sep 10 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Sep 04 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Aug 19 2025 |
| Raymond James |
Locked
➜
Locked
|
Locked | Jul 11 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barclays:
Locked
➜
Locked
|
Nov 07 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Sep 17 2025 |
|
Locked
Stifel:
Locked
➜
Locked
|
Sep 10 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Sep 10 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Sep 04 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Aug 19 2025 |
|
Locked
Raymond James:
Locked
➜
Locked
|
Jul 11 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
